Ipamorelin Frequently Asked Questions

Ipamorelin is a synthetic pentapeptide (5 amino acids) that acts as a selective growth hormone secretagogue. It stimulates the pituitary gland to release GH by activating the ghrelin/GHS receptor. Peptides Pharma Ipamorelin is formulated at >99% purity with 6 mg in a precision vial system.

Ipamorelin binds to the GHS-R on pituitary cells, triggering calcium-dependent GH release. Unlike other GH secretagogues, it is highly selective — it does not significantly stimulate ACTH, cortisol, or prolactin.

Researched for GH stimulation, body composition, bone density, sleep architecture, post-operative recovery, and age-related GH decline. Its selectivity is particularly valuable in studies requiring isolated GH elevation.

Via a lyophilized vial containing 6 mg in 3 mL. Designed for subcutaneous injection, typically timed for the evening or pre-sleep to complement natural GH secretion patterns.

Produced to >99% purity in GMP-certified facilities with ISO 7 cleanroom standards. Third-party HPLC and mass spectrometry validate every batch. Certificates of Analysis available on request.

Store at 2-8°C, protected from light. Do not freeze. Shelf life is 24 months when stored correctly.

Most commonly studied alongside CJC-1295. This combination targets two different GH-stimulating pathways for synergistic GH release. For research purposes only.

Each Peptides Pharma Ipamorelin vial is calibrated for a 30-day dosing period. The 6 mg / 3 mL formulation delivers precise daily doses throughout the full monthly research cycle.

Ipamorelin's defining characteristic is its selectivity — it produces a cleaner GH release without elevating cortisol, prolactin, or significantly stimulating appetite, unlike GHRP-6.

Legal to purchase in the UK for research purposes. Not a controlled substance and not approved for medical use. Peptides Pharma supplies exclusively for laboratory and research applications.